Literature DB >> 24726342

Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients.

Pierachille Santus1, Dejan Radovanovic2, Sonia Henchi3, Fabiano Di Marco4, Stefano Centanni5, Edgardo D'Angelo6, Matteo Pecchiari7.   

Abstract

BACKGROUND: In COPD patients, reversibility is currently evaluated from the changes of forced expiratory volume at 1s (ΔFEV1) and forced vital capacity (ΔFVC). By lowering peripheral airway smooth muscle tone, bronchodilators should decrease dynamic hyperinflation, gas trapping, and possibly dyspnea at rest. Hence, we hypothesize that specific airway resistance changes (ΔsRAW) should better characterize the acute response to bronchodilators.
METHODS: On two days, 60 COPD patients underwent dyspnea evaluation (VAS score) and pulmonary function testing at baseline and one hour after placebo or 300μg indacaterol administration.
RESULTS: Spirographic and ΔsRAW-based criteria identified as responders 24 and 45 patients, respectively. ΔsRAW correlated with changes of intrathoracic gas volume (ΔITGV) (r=0.61; p<0.001), residual volume (ΔRV) (r=0.60; p<0.001), ΔFVC (r=0.44; p=0.001), and ΔVAS (r=0.73; p<0.001), while ΔFEV1 correlated only with ΔFVC (r=0.34; p=0.008). Significant differences in terms of ΔITGV (p=0.002), ΔRV (p=0.023), and ΔVAS (p<0.001) occurred only if patients were stratified according to ΔsRAW.
CONCLUSIONS: In assessing the acute functional effect of bronchodilators, ΔsRAW-based criterion is preferable to FEV1-FVC-based criteria, being more closely related to bronchodilator-induced improvements of lung mechanics and dyspnea at rest.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adrenergic beta-agonists; Dyspnea; Plethysmography; Respiratory function tests; Reversibility; Short-term variability

Mesh:

Substances:

Year:  2014        PMID: 24726342     DOI: 10.1016/j.resp.2014.03.012

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  13 in total

1.  Bronchodilator Response in Patients with COPD, Asthma-COPD-Overlap (ACO) and Asthma, Evaluated by Plethysmographic and Spirometric z-Score Target Parameters.

Authors:  Richard Kraemer; Hans-Jürgen Smith; Fabian Gardin; Jürg Barandun; Stefan Minder; Lukas Kern; Martin H Brutsche
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-01

2.  Dynamic airway function during exercise in COPD assessed via impulse oscillometry before and after inhaled bronchodilators.

Authors:  Nicholas B Tiller; Min Cao; Fang Lin; Wei Yuan; Chu-Yi Wang; Asghar Abbasi; Robert Calmelat; April Soriano; Harry B Rossiter; Richard Casaburi; William W Stringer; Janos Porszasz
Journal:  J Appl Physiol (1985)       Date:  2021-05-20

Review 3.  LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.

Authors:  Nobuyuki Hizawa
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-10

4.  Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial.

Authors:  Pierachille Santus; Dejan Radovanovic; Silvia Di Marco; Vincenzo Valenti; Rita Raccanelli; Francesco Blasi; Stefano Centanni; Maurizio Bussotti
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-11

Review 5.  Effects of aclidinium on determinants of COPD severity: symptoms and quality of life.

Authors:  Marco Contoli; Paolo Solidoro; Fabiano Di Marco; Nicola Scichilone; Angelo Corsico; Fulvio Braido; Pierachille Santus
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-05

6.  Suppression of PTPN6 exacerbates aluminum oxide nanoparticle-induced COPD-like lesions in mice through activation of STAT pathway.

Authors:  Xiaobo Li; Hongbao Yang; Shenshen Wu; Qingtao Meng; Hao Sun; Runze Lu; Jian Cui; Yuxin Zheng; Wen Chen; Rong Zhang; Michael Aschner; Rui Chen
Journal:  Part Fibre Toxicol       Date:  2017-12-12       Impact factor: 9.400

7.  Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.

Authors:  Kathrin Kahnert; Tanja Lucke; Rudolf M Huber; Jürgen Behr; Frank Biertz; Anja Vogt; Henrik Watz; Peter Alter; Sebastian Fähndrich; Robert Bals; Rolf Holle; Stefan Karrasch; Sandra Söhler; Margarethe Wacker; Joachim H Ficker; Klaus G Parhofer; Claus Vogelmeier; Rudolf A Jörres
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

8.  Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.

Authors:  Joerg Salomon; Daiana Stolz; Guido Domenighetti; Jean-Georges Frey; Alexander J Turk; Andrea Azzola; Thomas Sigrist; Jean-William Fitting; Ulrich Schmidt; Thomas Geiser; Corinne Wild; Konstantinos Kostikas; Andreas Clemens; Martin Brutsche
Journal:  Respir Res       Date:  2017-01-11

Review 9.  Diagnostic Insights from Plethysmographic Alveolar Pressure Assessed during Spontaneous Breathing in COPD Patients.

Authors:  Camilla Zilianti; Pierachille Santus; Matteo Pecchiari; Edgardo D'Angelo; Dejan Radovanovic
Journal:  Diagnostics (Basel)       Date:  2021-05-21

10.  Taurine ameliorates particulate matter-induced emphysema by switching on mitochondrial NADH dehydrogenase genes.

Authors:  Xiaobo Li; Hongbao Yang; Hao Sun; Runze Lu; Chengcheng Zhang; Na Gao; Qingtao Meng; Shenshen Wu; Susanna Wang; Michael Aschner; Jiong Wu; Boping Tang; Aihua Gu; Steve A Kay; Rui Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.